Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean S Brummel

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 23, 2024
Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trialMarley D Bishop, Violet Korutaro, Ceejay L Boyce, et al.
Journal of the International AIDS Society|July 19, 2022
Clinical and population-based study design considerations to accelerate the investigation of new antiretrovirals during pregnancySean S Brummel, Jeff Stringer, Ed Mills, et al.
Plos One|January 31, 2020
The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomes-A randomized clinical trialPatience Atuhaire, Sean S Brummel, Blandina Theophil Mmbaga, et al.
AIDS (London, England)|March 23, 2021
In-utero exposure to zidovudine-containing antiretroviral therapy and clonal hematopoiesis in HIV-exposed uninfected newbornsShu-Hong Lin, Youjin Wang, Stephen W Hartley, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 2, 2024
Lipid and Glucose Profiles in Pregnant Women With HIV on Tenofovir-based Antiretroviral TherapyAhizechukwu C Eke, Sean S Brummel, Muktar H Aliyu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 9, 2024
Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) TrialGaerolwe Masheto, Sean S Brummel, Lauren Ziemba, et al.
HIV Clinical Trials|March 21, 2019
Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trialRisa M Hoffman, Konstantia Nadia Angelidou, Sean S Brummel, et al.
AIDS (London, England)|March 1, 2024
Effects of preterm birth, maternal ART and breastfeeding on 24-month infant HIV-free survival in a randomized trialSufia Dadabhai, Victoria B Chou, Mauricio Pinilla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 3, 2025
HIV resistance to dolutegravir varies with co-administered agentsIngrid A Beck, Ceejay L Boyce, Marley D Bishop, et al.
Lancet (London, England)|April 4, 2021
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trialShahin Lockman, Sean S Brummel, Lauren Ziemba, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 23, 2024
Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trialMarley D Bishop, Violet Korutaro, Ceejay L Boyce, et al.
Journal of the International AIDS Society|July 19, 2022
Clinical and population-based study design considerations to accelerate the investigation of new antiretrovirals during pregnancySean S Brummel, Jeff Stringer, Ed Mills, et al.
Plos One|January 31, 2020
The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomes-A randomized clinical trialPatience Atuhaire, Sean S Brummel, Blandina Theophil Mmbaga, et al.
AIDS (London, England)|March 23, 2021
In-utero exposure to zidovudine-containing antiretroviral therapy and clonal hematopoiesis in HIV-exposed uninfected newbornsShu-Hong Lin, Youjin Wang, Stephen W Hartley, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 2, 2024
Lipid and Glucose Profiles in Pregnant Women With HIV on Tenofovir-based Antiretroviral TherapyAhizechukwu C Eke, Sean S Brummel, Muktar H Aliyu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 9, 2024
Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) TrialGaerolwe Masheto, Sean S Brummel, Lauren Ziemba, et al.
HIV Clinical Trials|March 21, 2019
Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trialRisa M Hoffman, Konstantia Nadia Angelidou, Sean S Brummel, et al.
AIDS (London, England)|March 1, 2024
Effects of preterm birth, maternal ART and breastfeeding on 24-month infant HIV-free survival in a randomized trialSufia Dadabhai, Victoria B Chou, Mauricio Pinilla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 3, 2025
HIV resistance to dolutegravir varies with co-administered agentsIngrid A Beck, Ceejay L Boyce, Marley D Bishop, et al.
Lancet (London, England)|April 4, 2021
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trialShahin Lockman, Sean S Brummel, Lauren Ziemba, et al.
Pageof 5